Press Releases

Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Closing of Initial Public Offering and the Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

MALVERN, Pa., July 02, 2018 (GLOBE NEWSWIRE) — Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders and the maker of the NeuroStar® Advanced Therapy System, a non-drug, office-based therapy cleared by the FDA in 2008 to treat adult patients with Major Depressive Disorder who have not seen success with at least one antidepressant medication in the current episode, announced today the closing of its initial public offering of 6,325,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 825,000 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Neuronetics from the offering were $107.5 million, before deducting underwriting discounts and offering expenses. All of the shares in the offering were offered by Neuronetics. Neuronetics’ common stock is listed on the Nasdaq Global Market under the ticker symbol “STIM.”

For more information, click here.